Glennda Smithson

Immunology and Microbiology · Life Sciences

23h-index2.3kcitations50works2.02yr avg
OpenAlex↗ORCID↗Google Scholar↗

Accepting Students?

No reports yet. Know if this professor is taking students?

Research Topics

T-cell and B-cell Immunology(12), Immune Cell Function and Interaction(11), Immunotherapy and Immune Responses(8), Celiac Disease Research and Management(8), Monoclonal and Polyclonal Antibodies Research(6)

Publications50 total

Tu1336: PROXIMITY EXTENSION ASSAY-BASED PROTEOMICS UNCOVERS THE PLASMA SIGNATURE OF CELIAC DISEASE
Gastroenterology·2025
Biopsy Proteome Score Performs Well as an Effect Measure in a Gluten Challenge Trial of Celiac Disease
Clinical Gastroenterology and Hepatology·2024· 6 citedOpen Access
792 TAK-101 IMMUNOMODULATION OF THE GLIADIN RECALL RESPONSE IN HLA-DQ8 MICE: TREATMENT EFFECT DURATION AND MECHANISTIC STUDIES
Gastroenterology·2024
Tu1359 QUALIFICATION OF A MACHINE LEARNING APPROACH FOR THE ANALYSIS OF HIGH-DIMENSION IMMUNE-PROFILING DATA IN CELIAC DISEASE
Gastroenterology·2023
Sa1935 STRATEGIES FOR IMPROVING INTER-READER VARIABILITY OF VILLUS HEIGHT AND CRYPT DEPTH MEASUREMENTS ACROSS DIFFERENT INSTITUTIONS
Gastroenterology·2023· 1 cited
Measuring Serum Vedolizumab and Vedolizumab Antibodies: Comparison of Commercial Assays with the Vedolizumab Clinical Development Assay
Therapeutic Drug Monitoring·2023· 4 citedOpen Access
The Evolving Landscape of Biomarkers in Celiac Disease: Leading the Way to Clinical Development
Frontiers in Immunology·2021· 19 citedOpen Access
TAK-101 Nanoparticles Induce Gluten-Specific Tolerance in Celiac Disease: A Randomized, Double-Blind, Placebo-Controlled Study
Gastroenterology·2021· 167 citedOpen Access
A Phase I, Randomized, Double‐Blind, Placebo‐Controlled, Single‐Dose and Multiple‐Rising‐Dose Study of the BTK Inhibitor TAK‐020 in Healthy Subjects
Clinical and Translational Science·2021· 6 citedOpen Access
Development and validation of a <scp>high‐parameter</scp> mass cytometry workflow to decipher immunomodulatory changes in celiac disease
Cytometry Part B Clinical Cytometry·2021· 8 citedOpen Access
Evaluating Responses to Gluten Challenge: A Randomized, Double-Blind, 2-Dose Gluten Challenge Trial
Gastroenterology·2020· 93 citedOpen Access
630 TAK-101 (TIMP-GLIA) PREVENTS GLUTEN CHALLENGE INDUCED IMMUNE ACTIVATION IN ADULTS WITH CELIAC DISEASE
Gastroenterology·2020· 4 cited
Safety, tolerability, pharmacokinetics and pharmacodynamics of the anti‐CD38 cytolytic antibody TAK‐079 in healthy subjects
British Journal of Clinical Pharmacology·2020· 39 citedOpen Access
Decreased circulating CXCR3 + CCR9+T helper cells are associated with elevated levels of their ligands CXCL10 and CCL25 in the salivary gland of patients with Sjögren’s syndrome to facilitate their concerted migration
Scandinavian Journal of Immunology·2019· 22 citedOpen Access
675 Measuring Serum Vedolizumab and Antibodies to Vedolizumab: Comparison of Four Commercially Available Clinical Laboratory Assays to the Assay Used in Vedolizumab Development
The American Journal of Gastroenterology·2019· 1 cited
A Reduction in B, T, and Natural Killer Cells Expressing CD38 by TAK-079 Inhibits the Induction and Progression of Collagen-Induced Arthritis in Cynomolgus Monkeys
Journal of Pharmacology and Experimental Therapeutics·2019· 25 citedOpen Access
Coagulopathy, cryoprecipitate and CRYOSTAT-2: realising the potential of a nationwide trauma system for a national clinical trial
British Journal of Anaesthesia·2018· 39 citedOpen Access
FRI0241 The effect of febuxostat on inflammatory and cardiovascular biomarkers in hyperuricemic hypertensive patients
Annals of the Rheumatic Diseases·2018Open Access
SAT0226 A phase 1, randomized, double-blind, placebo-controlled, single- and multiple-rising dose study of the btk inhibitor tak-020 in healthy volunteers
Annals of the Rheumatic Diseases·2018· 3 citedOpen Access
Pharmacokinetics and pharmacodynamics of the cytolytic anti‐<scp>CD</scp>38 human monoclonal antibody <scp>TAK</scp>‐079 in monkey – model assisted preparation for the first in human trial
Pharmacology Research & Perspectives·2018· 12 citedOpen Access
page 1 of 3Next →

Frequent Co-authors

Kay L. Medina(7), Paul W. Kincade(6), Daniel A. Leffler(6), Eric R. Fedyk(5), Gary C. Starling(4), Stefan Roepcke(4), Lachy McLean(4), Robert Chervenak(4), P W Kincade(3), Ciarán P. Kelly(3), Joseph A. Murray(3), Adam Elhofy(3), P W Kincade(3), William J. McAuliffe(3), Lisa Borghesi(3), Lin‐Pierre Zhao(3), Lachy McLean(3), Ferenc Boldog(3), Wouter Korver(3), Josh Yuan(3)